

TIME (ET)	TIME (JT)	Session/Speaker
8:00 a.m. – 8:05 a.m.	9:00 p.m. – 9:05 p.m.	Introduction <i>Christophe Weber, president and CEO</i>
8:05 a.m. – 8:10 a.m.	9:05 p.m. – 9:10 p.m.	Delivering an Innovative Pipeline to Our Patients: Spotlight on Select Wave 1 Programs <i>Andy Plump, president of Research and Development</i>
8:10 a.m. – 8:35 a.m.	9:10 p.m. – 9:35 p.m.	Maribavir (TAK-620): Potential Game Changer in the Treatment for Post-Transplant Cytomegalovirus (CMV) Infection <i>Obi Umeh, global program lead, Rare Genetic and Hematology Therapeutic Area Unit</i> <i>Claus Jepsen, head of Global Product and Launch Strategy, Rare Genetic and Hematology Therapeutic Area Unit</i>
8:35 a.m. – 8:40a.m.	9:35 p.m. – 9:40p.m.	Break
8:40 a.m. – 9:00 a.m.	9:40 p.m. – 10:00 p.m.	Soticlestat (TAK-935): Novel MoA for Treatment of Dravet Syndrome and Lennox-Gastaut Syndrome <i>Sarah Sheikh, head of Neuroscience Therapeutic Area Unit</i> <i>Erika Gill, head of Global Product and Launch Strategy, Neuroscience Therapeutic Area</i>
9:00 a.m. – 9:35 a.m.	10:00 p.m. – 10:35 p.m.	Orexin Franchise Strategy Update: First Potential Medicine to Treat the Underlying Disease in Patients with Narcolepsy Type 1 <i>Elena Koundourakis, head of Orexin Franchise Development, Neuroscience Therapeutic Area</i> <i>Erika Gill, head of Global Product and Launch Strategy, Neuroscience Therapeutic Area</i>
9:35 a.m. – 9:40 a.m.	10:35 p.m. – 10:40 p.m.	Delivering an Innovative Pipeline to Our Patients: Spotlight on Select Wave 1 Programs <i>Ramona Sequeira, president of U.S. Business Unit & Global Portfolio Commercialization</i>
9:40 a.m. – 10:30 a.m.	10:40 p.m. – 11:30 p.m.	Panel Q&A Session